Aromatase inhibitors (AIs) are becoming the hormonal treatment of choice for postmenopausal women with early breast cancer. Large, well-controlled clinical studies have established the efficacy ...

Sjogren's syndrome usually occurs in women in their 50s and 60s. According to the 2023 data, 15,818 patients, or more than ...

AKT inhibitor Truqap (capivasertib) has been cleared by NICE for use in combination with standard therapy fulvestrant for ...

New research targets two critical enzymes involved in the production of the hormone estrogen – aromatase and steroid ...

[13] Since this 2004 study, aromatase inhibitor use and any effect on cognition remain under consideration. A 2009 ASCO Breast Cancer Symposium review of five studies evaluated the majority of ...

Today, we've recommended capivasertib (also called Truqap and made by AstraZeneca) with fulvestrant as an option for around 1,100 adults with hormone receptor (HR)-positive HER2-negative breast cancer ...

Early initiation of moderate-intensity aerobic exercise during aromatase inhibitor use reduced pain and prevented pain increases among postmenopausal women with breast cancer. Early initiation of ...

The trial evaluated the effectiveness of AstraZeneca’s camizestrant, an investigational next-generation oral selective ...

C, provided insights on what to consider when treating patients with HR+, HER2- breast cancer in the second line of treatment ...

Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...

Optimal lead follicle size of 19 to 23 mm was associated with improved clinical pregnancy rates among patients undergoing IUI.